Get started
Monte Rosa Therapeutics, Inc.Monte Rosa Therapeutics, Inc.Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

GLUE chart


Full chart

GLUE upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪274.33 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.03 USD
Net income (FY)
‪−72.70 M‬ USD
Revenue (FY)
‪75.62 M‬ USD
Shares float
‪45.99 M‬
Beta (1Y)
1.49

Employees


Employees (FY)
134
Change (1Y)
+1 +0.75%
Revenue / Employee (1Y)
‪564.34 K‬ USD
Net income / Employee (1Y)
‪−542.54 K‬ USD

About Monte Rosa Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Markus Warmuth
Website
monterosatx.com
Headquarters
Boston
Founded
2019
FIGI
BBG00X2VGZQ3
Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

GLUE news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as GLUE.

Frequently Asked Questions


The current price of GLUE is 4.81 USD — it has increased by 7.85% in the past 24 hours. Watch Monte Rosa Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Monte Rosa Therapeutics, Inc. stocks are traded under the ticker GLUE.
GLUE stock has risen by 9.07% compared to the previous week, the month change is a −31.77% fall, over the last year Monte Rosa Therapeutics, Inc. has showed a −17.92% decrease.
We've gathered analysts' opinions on Monte Rosa Therapeutics, Inc. future price: according to them, GLUE price has a max estimate of 20.00 USD and a min estimate of 10.00 USD. Watch GLUE chart and read a more detailed Monte Rosa Therapeutics, Inc. stock forecast: see what analysts think of Monte Rosa Therapeutics, Inc. and suggest that you do with its stocks.
GLUE reached its all-time high on Sep 7, 2021 with the price of 45.56 USD, and its all-time low was 2.44 USD and was reached on Oct 25, 2023. View more price dynamics on GLUE chart.
See other stocks reaching their highest and lowest prices.
GLUE stock is 7.87% volatile and has beta coefficient of 1.49. Track Monte Rosa Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Monte Rosa Therapeutics, Inc. there?
Today Monte Rosa Therapeutics, Inc. has the market capitalization of ‪274.33 M‬, it has increased by 9.11% over the last week.
Yes, you can track Monte Rosa Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Monte Rosa Therapeutics, Inc. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
GLUE earnings for the last quarter are 0.16 USD per share, whereas the estimation was 0.016 USD resulting in a 929.07% surprise. The estimated earnings for the next quarter are −0.40 USD per share. See more details about Monte Rosa Therapeutics, Inc. earnings.
Monte Rosa Therapeutics, Inc. revenue for the last quarter amounts to ‪60.62 M‬ USD, despite the estimated figure of ‪46.67 M‬ USD. In the next quarter, revenue is expected to reach ‪11.63 M‬ USD.
GLUE net income for the last quarter is ‪13.44 M‬ USD, while the quarter before that showed ‪−23.86 M‬ USD of net income which accounts for 156.32% change. Track more Monte Rosa Therapeutics, Inc. financial stats to get the full picture.
No, GLUE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 23, 2025, the company has 134 employees. See our rating of the largest employees — is Monte Rosa Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Monte Rosa Therapeutics, Inc. EBITDA is ‪−72.99 M‬ USD, and current EBITDA margin is −96.52%. See more stats in Monte Rosa Therapeutics, Inc. financial statements.
Like other stocks, GLUE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Monte Rosa Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Monte Rosa Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Monte Rosa Therapeutics, Inc. stock shows the sell signal. See more of Monte Rosa Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.